Treating chikungunya using HIV/AIDS drug efavirenz
Efavirenz, an HIV drug, shows potential for treating chikungunya virus, inhibiting replication and reducing viral load ...
The American Journal of Managed Care5d
Elimination of HIV Prevention Division Being Considered by Trump Administration
The HIV prevention division could be rolled into another department of the HHS as soon as the end of the week.
The Mail & Guardian12d
The endgame to HIV/Aids
The United States’ shutdown of HIV/Aids funding may harm global Aids programmes irreparably, jeopardising millions of lives ...
allAfrica.com on MSN11d
How much does our HIV response depend on US funding?
In the wake of US funding cuts for global aid, numerous donor-funded health facilities in South Africa have shut down and ...
Aidsmap8d
Broadly neutralising antibody N6LS could be part of long-acting HIV treatment
People living with HIV normally produce HIV-specific antibodies, but these mostly target parts of the virus that are hidden or highly variable. However, a small proportion of people naturally make ...
Monitor5dOpinion
Solutions to TB and HIV benefit all of us
It is important that the Global South and Global North continue to work together, finding solutions to these diseases that ...
Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
STAT27d
Q&A: How Trump’s USAID freeze halted the effort to develop an effective HIV vaccine in Africa
Last month, researchers in South Africa were preparing to administer two experimental HIV vaccines in a Phase ... a specific part of the envelope of the virus. Although we were targeting the ...
NBC News on MSN13d
Measles is unlike other viruses: What to know about long-term complications
Measles is unlike other childhood viruses. In severe cases, it can cause pneumonia. About 1 in 1,000 patients develops ...
Aidsmap13d
Lenacapavir plus broadly neutralising antibodies could be twice-yearly HIV treatment
People living with HIV normally produce HIV-specific antibodies, but these mostly target parts of the virus that are hidden or highly variable. However, a small proportion of people naturally make ...